Targeting poor proteasomal function with radioiodine eliminates CT26 colon cancer stem cells resistant to bortezomib therapy

We tested the hypothesis that tumor response to conventional bortezomib (BTZ) treatment is enhanced by targeted radiotherapy of resistant cancer stem cells (CSCs) that have characteristically poor proteasome function. This was accomplished by augmenting (131)I uptake through expression of a sodium-i...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jin Hee, Jung, Kyung-Ho, Park, Jin Won, Moon, Seung Hwan, Cho, Young Seok, Lee, Kyung-Han
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7459321/
https://www.ncbi.nlm.nih.gov/pubmed/32868872
http://dx.doi.org/10.1038/s41598-020-71366-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7459321/
https://www.ncbi.nlm.nih.gov/pubmed/32868872
http://dx.doi.org/10.1038/s41598-020-71366-3

Ejemplares similares